Net income
-213 million USD
2025-07-01 – 2026-06-30
Fundies. English
Neumora Therapeutics, Inc.
EDGAR24 filing records in this dataset, filed from 2023-08-25 to 2026-10-30. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 117 million USD Source
Exact value
116834000 USD
- Long-term debt including current maturities
- 52.9 million USD Source
Exact value
52912000 USD
- Shares outstanding
- 174 million shares Source
Exact value
174260000 shares
Reported share-count change
7.76% · 12.6 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Operating cash flow
-181 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -158485000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -111852000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -206440000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -158485000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -46404000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -85932000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -46404000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure
117 thousand USD
2023-01-01 – 2023-12-31
Exact inputs and evidence
- Capital expenditure: 36000 USD · 2023-01-01 – 2023-03-31 Source
- Capital expenditure: 36000 USD · 2023-01-01 – 2023-06-30 Source
- Capital expenditure: 36000 USD · 2023-01-01 – 2023-03-31 Source
- Capital expenditure: 73000 USD · 2023-01-01 – 2023-09-30 Source
- Capital expenditure: 36000 USD · 2023-01-01 – 2023-06-30 Source
- Capital expenditure: 117000 USD · 2023-01-01 – 2023-12-31 Source
- Capital expenditure: 73000 USD · 2023-01-01 – 2023-09-30 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-30.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 4 of 11 periods available· newest 2025-12-31
- Net income: 4 of 11 periods available· newest 2025-12-31
- Operating cash flow: 4 of 11 periods available· newest 2025-12-31
- Capital expenditure: 2 of 11 periods available· newest 2023-12-31
- Total assets: 4 of 11 periods available· newest 2025-12-31
- Total liabilities: 4 of 11 periods available· newest 2025-12-31
- Current assets: 4 of 11 periods available· newest 2025-12-31
- Current liabilities: 4 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 4 of 11 periods available· newest 2025-12-31
- Long-term debt including current maturities: 1 of 11 periods available· newest 2025-12-31
- Shares outstanding: 4 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
+USD 6.86 millionPrior period
−USD 243.79 million
–
Current period
−USD 236.93 million
–
Exact inputs and evidence
-236928000 − -243787000 = 6859000 USD
-243787000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-236928000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 23.5 millionPrior period
−USD 182.94 million
–
Current period
−USD 206.44 million
–
Exact inputs and evidence
-206440000 − -182936000 = -23504000 USD
-182936000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-206440000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2022 2022-01-01 – 2022-12-31 | −USD 130.9 million Exact valueExact value: -130904000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 114.9 million Exact valueExact value: -114896000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 511,000 Exact valueExact value: 511000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 115.41 million Calculation and evidence-114896000 − 511000 USD Exact free cash flow: -115407000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2023 2023-01-01 – 2023-12-31 | −USD 235.93 million Exact valueExact value: -235925000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 163.28 million Exact valueExact value: -163278000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 117,000 Exact valueExact value: 117000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 163.4 million Calculation and evidence-163278000 − 117000 USD Exact free cash flow: -163395000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | −USD 243.79 million Exact valueExact value: -243787000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 182.94 million Exact valueExact value: -182936000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 236.93 million Exact valueExact value: -236928000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 206.44 million Exact valueExact value: -206440000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
24 filings · 861 latest values · 861 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001885522, 1885522, NMRA, edgar:1885522
Also known as NEUMORA THERAPEUTICS, INC., Neumora Therapeutics, Inc.